Dr. Volker Lodwig joins EIT Health Supervisory Board

He will represent EIT Health Germany’s Partners

EIT Health welcomes Dr. Volker Lodwig, Head of Public Policy at Roche Diagnostics GmbH, as a new Member of our Supervisory Board. His appointment, as a representative of EIT Health Germany, was confirmed at the EIT Health Partner Assembly on 10 September 2020.

Dr. Lodwig has been a strong supporter of EIT Health since its early days, initially serving as a Member of the Executive Committee of InnoLife (the consortium later selected by the EIT to become EIT Health) between 2008 and 2014, and subsequently serving as the Managing Coordinator of EIT Health e.V. during EIT Health’s establishment in 2015. Additionally, he has been an active Member of the EIT Health Germany Supervisory Board since 2015, which he also chaired between 2015 and 2019.

Dr. Lodwig holds degrees in education, physics and philosophy, including a PhD in atomic physics obtained from Ruhr-University Bochum. For the past 30 years, he has been working for Roche, taking up a variety of roles within the corporation and continually establishing and fostering collaborations with universities to turn basic research into applied research at Roche. Dr. Lodwig is also strongly engaged in the company’s participation in Horizon 2020 and leading cluster projects. He has co-authored 40+ scientific publications.

“The appointment to the EIT Health e.V. Supervisory board is an excellent opportunity to contribute to EIT Health’s work and to ensure its activities deliver impact for all Europeans well into the future. I am committed to actively living the knowledge triangle which is at the core of the EIT’s philosophy and feel honoured and am very grateful for the trust placed in me by the community, particularly the CLCs whose vital role I aim to strengthen within this pan-European partnership.” said Dr. Lodwig on his appointment.

Dr. Lodwig succeeds Dr. Ursula Redeker, retired Spokesperson of the Board of Roche Diagnostics, and Prof. Joachim Hornegger, President of the FAU Erlangen-Nürnberg, who represented EIT Health Germany’s industrial and academic Partners on the EIT Health Supervisory Board since 2015 and 2018, respectively. Going forward Dr. Redeker will continue her involvement with EIT Health as an Independent Member of the EIT Health Supervisory Board, whilst Dr. Lodwig will join the same board to represent all academic and industrial Partners from EIT Health Germany, which includes Partners from Germany, Austria and Switzerland.

Prof. Dr. Catherine Disselhorst-Klug, Chairwoman of the EIT Health Germany Supervisory Board, and Dr. Katharina Ladewig, Managing Director of EIT Health Germany, express their thanks to Dr. Redeker and Prof. Hornegger for their past service, and congratulate Dr. Lodwig on his appointment.